Clinical trials: copd or chronic obstructive
Asthma, COPD
The Effects of Broccoli Sprout Extract on Obstructive Lung Disease
The purpose of this study is to examine whether broccoli sprout extract can effect lung function measurements in individuals with asthma and COPD.
- Trial name
- NCT00994604
- Testing
- broccoli sprout extract
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Pulmonary Disease, Chronic Obstructive
Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)
This is a randomised, double-blind, parallel-group, multi-centre study evaluating 15 milligram (mg) twice daily/ Bi-daily (BID) of losmapimod versus placebo, in addition to standard of care (SoC).
- Trial name
- NCT02299375
- Testing
- Losmapimod tablets, Salbutamol MDI
- Where
- 36 sites in Argentina, Brazil and 6 more
- Volunteers
- 184 people
- Sponsor
- GlaxoSmithKline
COPD Exacerbation
COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers
The purpose of this study is to compare drug delivery and lung function after treatment with formoterol from a nebulizer versus a dry powder inhaler (DPI) in patients recovering from severe exacerbations of COPD.
- Trial name
- NCT02291016
- Testing
- Formoterol
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Tennessee Graduate School of Medicine
Chronic Obstructive Pulmonary Disease
Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)
This is a single cohort, prospective post approval study conducted on patients with COPD in Canada. The study will enroll patients that have not responded to their current treatment of tiotropium alone, or who are on the fixed…
- Trial name
- POWER (NCT02202616)
- Testing
- Glycopyrronium /Indacaterol maleate
- Where
- Canada
- Volunteers
- 401 people
- Sponsor
- Novartis Pharmaceuticals
Migraine Disorders
Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE
The primary objective of this study is to evaluate the safety and efficacy of occipital nerve stimulation (ONS) using the Boston Scientific Corporation (BSC) Precision™ System in the management of intractable chronic migraine…
- Trial name
- OPTIMISE (NCT01775735)
- Testing
- Occipital nerve stimulator
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Boston Scientific Corporation
Pulmonary Disease, Chronic Obstructive
12 / 48 Week Pivotal PFT vs PBO in COPD I
This primary objective of this study is to compare two doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily to placebo in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00782210
- Testing
- Olodaterol (BI1744)
- Where
- 54 sites in United States, Australia and 4 more
- Volunteers
- 625 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary aim of this study is to investigate the tolerability and safety of AZD 1236 compared with placebo ("inactive substance") in COPD patients by assessment of Adverse Events, vital signs and laboratory safety assessments.
- Trial name
- CERA (NCT00758459)
- Testing
- AZD1236
- Where
- 14 sites in Bulgaria, Finland and 3 more
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary objective of the study is to evaluate structural changes effected by AD9668 in the airways of adults with Chronic Obstructive Pulmonary Disease (COPD) by Multi-Slice Computed Tomography (MSCT)
- Trial name
- NCT01054170
- Testing
- AZD9668
- Where
- 9 sites in Canada, Denmark and 3 more
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
COPD, Eosinophilia
Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
This is a single-centre, double-blinded, randomised, placebo controlled trial comparing mepolizumab 100mg versus placebo in patients with eosinophilic COPD, started following their index admission to hospital.
- Trial name
- COPD-HELP (NCT04075331)
- Testing
- Mepolizumab
- Where
- United Kingdom
- Volunteers
- 238 people
- Sponsor
- University of Leicester
COPD Exacerbation
Molecular Breath Print of COPD Patients With Exacerbations Despite Triple Inhalational Therapy
Determination of specific molecular breath patterns by secondary electrospray ionization mass spectrometry (SESIHRMS) during and 8 weeks after a COPD exacerbation.
- Trial name
- TripleEX (NCT04638920)
- Testing
- No intervention
- Where
- Switzerland
- Volunteers
- 35 people
- Sponsor
- Malcolm Kohler
Pancreatitis, Chronic; Diabetes; Transplant
Anti-inflammatory Therapy to Improve Outcomes After TPIAT
Patients with severe chronic pancreatitis may be candidates to have their pancreas removed and their islets transplanted into the liver to reduce the risk of diabetes mellitus, a procedure called total pancreatectomy with islet…
- Trial name
- NCT02713997
- Testing
- etanercept, Alpha 1-Antitrypsin
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Minnesota
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
This study assessed the efficacy and safety of indacaterol (150 µg once daily [od]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease…
- Trial name
- INTRUST2 (NCT00877383)
- Testing
- Indacaterol 150 μg, Tiotropium 18 μg
- Where
- 176 sites in United States, Canada and 7 more
- Volunteers
- 1,142 people
- Sponsor
- Novartis Pharmaceuticals
Malnutrition
COPD: Oral Nutrition Supplements vs. Energy- and Protein Dense in Between Meal Snacks.
At least one fifth of patients in European hospitals are malnourished. Malnutrition is associated with negative consequences, including higher rates of complications, longer hospital stay, impaired wound healing and increased…
- Trial name
- COPD (NCT02251496)
- Testing
- In between meals snacks (Snacks-group), Oral nutrition supplement (ONS-group)
- Where
- Iceland
- Volunteers
- 34 people
- Sponsor
- University of Iceland
COPD
Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD
The purpose of the study is to determine whether PIF is clinically important when using the Ellipta DPI device. In addition, the study will validate the best/most clinically appropriate way to perform a PIF maneuver, to determine…
- Trial name
- NCT04606394
- Testing
- Trelegy Ellipta 100/62.5/25Mcg Inh 30D, Ventolin 90Mcg/Actuation Inhalation Aerosol
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pulmonary Research Institute of Southeast Michigan
Pulmonary Disease, Chronic Obstructive
Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated With Chronic Obstructive Pulmonary Disease
The purpose of this study is to determine if long-term administration of a macrolide antibiotic will reduce worsening of symptoms among individuals with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00325897
- Testing
- Macrolide Antibiotic (Azithromycin)
- Where
- 10 sites in United States
- Volunteers
- 1,142 people
- Sponsor
- University of Minnesota
Positive-Pressure Respiration, Communication
Determining the Benefits of Improving Communication in BPAP/CPAP Users
The purpose of this study is to determine the effectiveness of a non-invasive communication aid for BPAP/CPAP masks. This study also looks to determine the potential impact of the device on patients with obstructive sleep apnea…
- Trial name
- NCT03795753
- Testing
- F2S Communicator, Non-functioning Communicator
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Emory University
Pulmonary Disease, Chronic Obstructive
BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH
The aim of the present study is to evaluate the effect of aclidinium bromide 400 μg BID compared with placebo on COPD symptoms in a symptomatic patients population with moderate COPD and chronic bronchitis, and particularly…
- Trial name
- M-34273-46 (NCT02375724)
- Testing
- Aclidinium Bromide
- Where
- 24 sites in Germany, Hungary and 3 more
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)
To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.
- Trial name
- NCT00363896
- Testing
- Aclidinium bromide
- Where
- 132 sites in Andorra, Austria and 14 more
- Volunteers
- 843 people
- Sponsor
- AstraZeneca
Chronic Graft Versus Host Disease
Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
This pilot clinical trial studies how well vismodegib works in treating patients with chronic graft-versus-host disease that did not respond to previous steroid treatment.
- Trial name
- NCT02337517
- Testing
- Laboratory Biomarker Analysis, Vismodegib
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Obstructive Pulmonary Disease (COPD)
Study Evaluating Preference, Satisfaction and Ease of Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Diagnosed Patients
Preference study: Genuair vs HandiHaler inhalers in COPD patients.
- Trial name
- NCT01385696
- Testing
- Genuair® (Almirall S.A.), HandiHaler® (Boehringer Ingelheim's)
- Where
- 4 sites in Germany, Netherlands
- Volunteers
- 130 people
- Sponsor
- Almirall, S.A.